I was once told, that success breeds success and today has been one of those times. From yesterday’s slight win, we have continued our climb from the cellar with a rousing 2% gain, and another 3% during after hours. 5% daily returns is something dreams are made of, and I hope that the nightmare isn’t right around the corner.
As I go through Chapter 3, the one thing that I’ve yet to understand, is how IFRX was ever in the $30-$50 per share range, with yearly losses growing at 100%. I guess when you play with the stock market though, things like these happen. Last year, IFRX had a EBITDA of -$44.41M, so it was only a matter of time before the price was rocked and dropped to its current $3.43. What the question is though, is how does IFRX compare? To be honest, not bad. Many biotech companies that trade within the ‘penny stock’ range, often have yearly losses until a drug or two makes a breakthrough, the company goes bankrupt, or it is absorbed by one of the larger pharmaceutical firms (Johnson/Johnson, Merck, Pfizer) at which time, the investor angels cash in, and move on.
In the end, only time will tell if we climb out of this darkness but just remember that when you’re down, you never think you’ll be up again, but life goes on. Maybe it’ll go on to that mythical $30 again and we can talk about how great life is again.
IFRX 